Shares of Flexion Therapeutics, Inc. (NASDAQ:FLXN) have been assigned a consensus recommendation of “Buy” from the eleven brokerages that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, seven have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $32.00.

A number of research firms recently commented on FLXN. Zacks Investment Research raised shares of Flexion Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, July 5th. Wells Fargo & Company reissued an “outperform” rating and set a $30.00 target price on shares of Flexion Therapeutics in a research report on Saturday, March 25th. Royal Bank Of Canada set a $44.00 target price on shares of Flexion Therapeutics and gave the company a “buy” rating in a research report on Sunday, March 26th. ValuEngine raised shares of Flexion Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, June 21st. Finally, Janney Montgomery Scott reissued a “buy” rating and set a $35.00 target price (up previously from $30.00) on shares of Flexion Therapeutics in a research report on Wednesday, July 12th.

ILLEGAL ACTIVITY NOTICE: This piece was published by American Banking News and is owned by of American Banking News. If you are viewing this piece on another site, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be read at https://www.americanbankingnews.com/2017/07/21/flexion-therapeutics-inc-flxn-given-average-rating-of-buy-by-brokerages.html.

Shares of Flexion Therapeutics (NASDAQ FLXN) traded up 1.02% during trading on Friday, reaching $23.82. 403,405 shares of the company were exchanged. The firm’s market capitalization is $756.45 million. The company’s 50-day moving average is $20.08 and its 200 day moving average is $20.83. Flexion Therapeutics has a 1-year low of $15.44 and a 1-year high of $29.41.

Flexion Therapeutics (NASDAQ:FLXN) last posted its earnings results on Thursday, May 4th. The specialty pharmaceutical company reported ($0.75) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.73) by $0.02. Equities research analysts expect that Flexion Therapeutics will post ($3.56) EPS for the current fiscal year.

In related news, insider Michael D. Clayman purchased 5,000 shares of the firm’s stock in a transaction on Monday, June 5th. The stock was acquired at an average price of $17.23 per share, with a total value of $86,150.00. Following the completion of the acquisition, the insider now owns 20,146 shares in the company, valued at approximately $347,115.58. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Mark Stejbach purchased 1,580 shares of the firm’s stock in a transaction on Friday, June 16th. The stock was bought at an average cost of $17.02 per share, with a total value of $26,891.60. The disclosure for this purchase can be found here. Company insiders own 15.98% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Verde Servicos Internacionais S.A. bought a new position in Flexion Therapeutics during the second quarter worth about $1,167,000. Driehaus Capital Management LLC boosted its position in Flexion Therapeutics by 16.3% in the first quarter. Driehaus Capital Management LLC now owns 523,060 shares of the specialty pharmaceutical company’s stock worth $14,076,000 after buying an additional 73,353 shares in the last quarter. Credit Suisse AG boosted its position in Flexion Therapeutics by 109.4% in the first quarter. Credit Suisse AG now owns 38,177 shares of the specialty pharmaceutical company’s stock worth $1,027,000 after buying an additional 19,948 shares in the last quarter. Ionic Capital Management LLC bought a new position in Flexion Therapeutics during the first quarter worth about $4,571,000. Finally, State Street Corp boosted its position in Flexion Therapeutics by 111.8% in the first quarter. State Street Corp now owns 829,254 shares of the specialty pharmaceutical company’s stock worth $22,316,000 after buying an additional 437,648 shares in the last quarter. 75.16% of the stock is owned by institutional investors and hedge funds.

Flexion Therapeutics Company Profile

Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.

Analyst Recommendations for Flexion Therapeutics (NASDAQ:FLXN)

Receive News & Ratings for Flexion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.